Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Director | June 16, 2023 | June 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2033-06-15 | Direct | 62,500 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 62,500 · Balance 62,500 F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 21, 2023 23:14 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001854270-23-000077 · wk-form4_1687389279.xml · derivative · entry 1 Berland Susan D · CIK 0001307002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 22:00 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-22-026139 · doc4.xml · derivative · entry 1 Berland Susan D · CIK 0001307002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-07-12 F1 · derivative.exercise_date: The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.